Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Acquisition

 Dear Sir/Madam, In accordance with the requirements of regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, the company would like to announce acquisition of nine dermatology brands from Dr.Reddy''s Laboratories Ltd. The further details are tabulated in Annexure I. The details of the same will also be uploaded on the website of the Company.
16-03-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 ALLOTMENT OF EQUITY SHARES PURSUANT TO ESOP-2021 SCHEME
02-03-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
28-02-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
15-02-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
14-02-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
09-02-2023

What is driving growth for pharma major Eris Lifesciences?

 Eris Lifesciences recently acquired nine brands from Glenmark, consisting of derma portfolio for Rs 340 crore, with topmost brands having a leadership position in the pharmaceutical market
25-01-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Dear Sir/Madam, This is to inform that the transcript of the Analyst and Investor call which was held after the announcement of financial results for the quarter ended, 31st December 2022 is available on our website URL https://eris.co.in/financials/ (File name: Transcript of the Analyst and Investor Conference Call Q3FY23).
23-01-2023
Bigul

Eris Lifesciences Ltd - 540596 - INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

 Dear Sir/Madam, We would like to inform that the Company has given a corporate guarantee in favour of Eris Oaknet Healthcare Private Limited ('EOHPL'), a Wholly Owned Subsidiary, for securing the Credit facility(ies) that it availed from HDFC Bank. Further, in accordance requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B (11) of Part A to the Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herewith may please be taken on record. The details of the same will also be uploaded on the website of the Company.
23-01-2023
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING
19-01-2023
Next Page
Close

Let's Open Free Demat Account